0001209191-20-019430.txt : 20200316
0001209191-20-019430.hdr.sgml : 20200316
20200316213950
ACCESSION NUMBER: 0001209191-20-019430
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200316
FILED AS OF DATE: 20200316
DATE AS OF CHANGE: 20200316
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ho Robert
CENTRAL INDEX KEY: 0001806254
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36327
FILM NUMBER: 20719098
MAIL ADDRESS:
STREET 1: 360-1616 EASTLAKE AVENUE EAST
CITY: SEATTLE
STATE: WA
ZIP: 98102
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Neoleukin Therapeutics, Inc.
CENTRAL INDEX KEY: 0001404644
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: SUITE 360 - 1616 EASTLAKE AVE EAST
CITY: SEATTLE
STATE: WA
ZIP: 98102
BUSINESS PHONE: 206-732-2133
MAIL ADDRESS:
STREET 1: SUITE 360 - 1616 EASTLAKE AVE EAST
CITY: SEATTLE
STATE: WA
ZIP: 98102
FORMER COMPANY:
FORMER CONFORMED NAME: AQUINOX PHARMACEUTICALS, INC
DATE OF NAME CHANGE: 20140128
FORMER COMPANY:
FORMER CONFORMED NAME: AQUINOX PHARMACEUTICALS (USA) INC
DATE OF NAME CHANGE: 20070626
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-03-16
0
0001404644
Neoleukin Therapeutics, Inc.
NLTX
0001806254
Ho Robert
C/O NEOLEUKIN THERAPEUTICS, INC.
360-1616 EASTLAKE AVENUE E.
SEATTLE
WA
98102
0
1
0
0
Chief Financial Officer
Restricted Stock Units
0.00
2020-03-16
4
A
0
75000
0.00
A
Common Stock
75000
75000
D
Stock Option (Right to Buy)
6.44
2020-03-16
4
A
0
200000
0.00
A
2030-03-16
Common Stock
200000
200000
D
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
The RSUs will vest as to 1/3 of the total number of shares underlying the award on each of March 16, 2021, March 16, 2022 and March 16, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
The RSUs do not expire; these securities either vest and settle or are canceled prior to the vesting date.
The option vests as to 1/4 of the total shares on March 16, 2021, and then 1/48 of the total shares will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
/s/ Kris McGrew, as Attorney-in-Fact for Robert Ho
2020-03-16